Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 51


Restoring physiological levels of ascorbate slows tumor growth and moderates HIF-1 pathway activity in Gulo(-/-) mice.

Campbell EJ, Vissers MC, Bozonet S, Dyer A, Robinson BA, Dachs GU.

Cancer Med. 2015 Feb;4(2):303-14. doi: 10.1002/cam4.349. Epub 2014 Oct 30.


Current limitations of murine models in oncology for ascorbate research.

Campbell EJ, Dachs GU.

Front Oncol. 2014 Oct 14;4:282. doi: 10.3389/fonc.2014.00282. eCollection 2014. Review.


Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5.

Wang J, Guise CP, Dachs GU, Phung Y, Hsu AH, Lambie NK, Patterson AV, Wilson WR.

Biochem Pharmacol. 2014 Oct 15;91(4):436-46. doi: 10.1016/j.bcp.2014.08.003. Epub 2014 Aug 15.


Tumour cells expressing single VEGF isoforms display distinct growth, survival and migration characteristics.

Kanthou C, Dachs GU, Lefley DV, Steele AJ, Coralli-Foxon C, Harris S, Greco O, Dos Santos SA, Reyes-Aldasoro CC, English WR, Tozer GM.

PLoS One. 2014 Aug 13;9(8):e104015. doi: 10.1371/journal.pone.0104015. eCollection 2014.


Regulation of the 2-oxoglutarate-dependent dioxygenases and implications for cancer.

Vissers MC, Kuiper C, Dachs GU.

Biochem Soc Trans. 2014 Aug;42(4):945-51. doi: 10.1042/BST20140118. Review.


Increased Tumor Ascorbate is Associated with Extended Disease-Free Survival and Decreased Hypoxia-Inducible Factor-1 Activation in Human Colorectal Cancer.

Kuiper C, Dachs GU, Munn D, Currie MJ, Robinson BA, Pearson JF, Vissers MC.

Front Oncol. 2014 Feb 4;4:10. doi: 10.3389/fonc.2014.00010. eCollection 2014.


Intracellular ascorbate enhances hypoxia-inducible factor (HIF)-hydroxylase activity and preferentially suppresses the HIF-1 transcriptional response.

Kuiper C, Dachs GU, Currie MJ, Vissers MC.

Free Radic Biol Med. 2014 Apr;69:308-17. doi: 10.1016/j.freeradbiomed.2014.01.033. Epub 2014 Feb 2.


Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells.

Volkova E, Robinson BA, Willis J, Currie MJ, Dachs GU.

Oncol Lett. 2014 Feb;7(2):311-320. Epub 2013 Nov 27.


Consumption of vitamin C is below recommended daily intake in many cancer patients and healthy volunteers in Christchurch.

Dachs GU, Munn DG, Carr AC, Vissers MC, Robinson BA.

N Z Med J. 2014 Mar 7;127(1390):73-6. No abstract available.


Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.

Currie MJ, Beardsley BE, Harris GC, Gunningham SP, Dachs GU, Dijkstra B, Morrin HR, Wells JE, Robinson BA.

Hum Pathol. 2013 Mar;44(3):402-11. doi: 10.1016/j.humpath.2012.06.004. Epub 2012 Oct 1.


Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro.

Hunt MA, Li D, Hay MP, Currie MJ, Robinson BA, Patterson AV, Dachs GU.

J Gene Med. 2012 Jan;14(1):62-74. doi: 10.1002/jgm.1635.


Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.

Guise CP, Abbattista MR, Tipparaju SR, Lambie NK, Su J, Li D, Wilson WR, Dachs GU, Patterson AV.

Mol Pharmacol. 2012 Jan;81(1):31-40. doi: 10.1124/mol.111.073759. Epub 2011 Oct 7.


Angiogenesis and host immune response contribute to the aggressive character of non-melanoma skin cancers in renal transplant recipients.

Mackenzie KA, Miller AP, Hock BD, Gardner J, Simcock JW, Roake JA, Dachs GU, Robinson BA, Currie MJ.

Histopathology. 2011 May;58(6):875-85. doi: 10.1111/j.1365-2559.2011.03845.x.


Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer.

Volkova E, Willis JA, Wells JE, Robinson BA, Dachs GU, Currie MJ.

Br J Cancer. 2011 Jan 4;104(1):51-9. doi: 10.1038/sj.bjc.6606005. Epub 2010 Nov 16.


A profile of prognostic and molecular factors in European and Māori breast cancer patients.

Dachs GU, Kano M, Volkova E, Morrin HR, Davey VC, Harris GC, Cheale M, Frampton C, Currie MJ, Wells JE, Robinson BA.

BMC Cancer. 2010 Oct 10;10:543. doi: 10.1186/1471-2407-10-543.


Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer.

Kuiper C, Molenaar IG, Dachs GU, Currie MJ, Sykes PH, Vissers MC.

Cancer Res. 2010 Jul 15;70(14):5749-58. doi: 10.1158/0008-5472.CAN-10-0263. Epub 2010 Jun 22.


The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.

Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV.

Cancer Res. 2010 Feb 15;70(4):1573-84. doi: 10.1158/0008-5472.CAN-09-3237. Epub 2010 Feb 9.


In vivo characterization of horseradish peroxidase with indole-3-acetic acid and 5-bromoindole-3-acetic acid for gene therapy of cancer.

Tupper J, Stratford MR, Hill S, Tozer GM, Dachs GU.

Cancer Gene Ther. 2010 Jun;17(6):420-8. doi: 10.1038/cgt.2009.86. Epub 2010 Jan 15.


Bystander or no bystander for gene directed enzyme prodrug therapy.

Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV.

Molecules. 2009 Nov 10;14(11):4517-45. doi: 10.3390/molecules14114517. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk